“The challenge with state-level out-of-pocket caps for insulin is that the caps are often focused on commercial enrollees, many of whom already have out-of-pocket costs below the out-of-pocket cap levels,” said Kelly Anderson, an assistant professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences.